UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private
Issuer
Pursuant to Rule 13a-16
or 15d-16
of the Securities Exchange
Act of 1934
For the month of February
2026
Commission File Number:
001-36000
XTL Biopharmaceuticals Ltd.
(Exact name of Registrant as specified in its charter)
85 Medinat ha-Yehudim St.
Herzliya,
4676670, Israel
(Address of principal
executive offices)
Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
On
February 17, 2026, XTL Biopharmaceuticals Ltd. (the “Company”) convened an Extraordinary General Meeting of Shareholders
(the “Extraordinary General Meeting”). However, the Extraordinary General Meeting was adjourned for one week to the same
day, time and place due to lack of quorum. Accordingly, the Extraordinary General Meeting will be reconvened on Tuesday, February 24,
2026 at 4:00 p.m., Israel time, at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul
Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
XTL BIOPHARMACEUTICALS LTD. |
| |
|
| Date: February 17, 2026 |
/s/ Noam Band |
| |
Noam Band
Chief Executive Officer |
2